In the News

March 13, 2019: Emtora Biosciences CEO Talks New Name, Focus, and Finish Line

February 28, 2019: Rapamycin Holdings Becomes Emtora Biosciences, Gains New CEO

February 26, 2019: San Antonio Biotech Changing its Name and CEO

February 26, 2019: Rapamycin Holdings Changes Name to Emtora Biosciences, Hires New CEO

November 1, 2018: SA Drug Development Company Reaches Major Milestone

May 9, 2018: Rapamycin Holdings Plans Tests of eRapa for Prostate Cancer

October 17, 2017: San Antonio Drug Developer Obtains Key Patent Approval in Path to Market

August 7, 2017: New Rapamycin CEO Hired to Handle Funding, FDA Inflection Points

April 6, 2015: Drug Designed in San Antonio Fights Age-Related Diseases